The Antidiarrheal Efficacy of a Proprietary Amino Acid Mixture (enterade®) in Neuroendocrine Tumor (NETs) Patients.

Aman Chauhan1,2, Rachel C Miller2, Qian Yu2, Laura P Luque4, Lowell Brian Anthony1,2
1 Department of Internal Medicine, Division of Medical Oncology, Markey Cancer Center, University of Kentucky Lexington, KY; 2 Dietitian Consultant Markey Cancer Center; 3 University of Kentucky School of Medicine; 4 Entiric Health Solutions Inc.

INTRODUCTION

Based on SEER database, gastroenteropancreatic neuroendocrine tumor (GEPNET) incidence has increased 6-fold over past 3 decades.

We conducted a retrospective chart review to evaluate antidiarrheal efficacy of enterade® in neuroendocrine tumor patients with quality of life limiting diarrhea.

METHODS

Medical records of all the GEPNET patients treated with enterade® for symptomatic diarrhea were evaluated.

Patients were treated at Markey Cancer Center between May 2017–June 2018.

DEMOGRAPHICS/RESULTS

- A total of 69 patients were given enterade®.
  - enterade® was administered as an 8oz bottle BID for 1 week.
  - Antidiarrheal efficacy data was available on 41 patients.
  - 15 patients had small bowel neuroendocrine tumors (NET), 5 had bronchial NETs, 2 had colorectal NETs, 3 had NETs of unknown primary, 3 had gastric NETs, 3 had pancreas NETs and one was high grade neuroendocrine carcinoma of prostate.
  - 21 patients had history of prior bowel resection either for primary neuroendocrine tumor resection or debulking.
  - 25 patients were on somatostatin analogs at the time of initiation of enterade®.

<table>
<thead>
<tr>
<th>PT #</th>
<th>Type of NET</th>
<th>SSA T</th>
<th>Baseline BM Frequency</th>
<th>Post-enterade® BM Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>pancreatic NET</td>
<td>No</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>midgut NET</td>
<td>Yes</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>gastric NET</td>
<td>No</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>bronchial NET</td>
<td>Yes</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>bronchial NET</td>
<td>No</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>NET of unknown primary</td>
<td>No</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>17</td>
<td>bronchial NET</td>
<td>Yes</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>metastatic prostatic NEC</td>
<td>No</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>midgut NET</td>
<td>No</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>midgut NET</td>
<td>Yes</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>midgut NET</td>
<td>Yes</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>12</td>
<td>metastatic pulmonary NET</td>
<td>No</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>midgut NET</td>
<td>Yes</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>mixed colorectal/cecal adenocarcinoma</td>
<td>No</td>
<td>15</td>
<td>3</td>
</tr>
<tr>
<td>15</td>
<td>bronchial NET</td>
<td>No</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>16</td>
<td>midgut NET</td>
<td>Yes</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>17</td>
<td>pancreatic NET</td>
<td>Yes</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>18</td>
<td>midgut NET</td>
<td>Yes</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>19</td>
<td>Bronchial NET</td>
<td>No</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>20</td>
<td>midgut NET</td>
<td>No</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>21</td>
<td>midgut NET</td>
<td>Yes</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>22</td>
<td>midgut NET</td>
<td>Yes</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>23</td>
<td>Gastric NET</td>
<td>Yes</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>24</td>
<td>midgut NET</td>
<td>Yes</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>25</td>
<td>midgut NET</td>
<td>No</td>
<td>20</td>
<td>2</td>
</tr>
<tr>
<td>26</td>
<td>pancreatic NET</td>
<td>No</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>27</td>
<td>NET of unknown primary</td>
<td>Yes</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>28</td>
<td>pancreatic NET</td>
<td>Yes</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>29</td>
<td>midgut NET</td>
<td>No</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>30</td>
<td>Duodenal NET</td>
<td>No</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>31</td>
<td>Bronchial NET</td>
<td>Yes</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>32</td>
<td>pancreatic NET</td>
<td>Yes</td>
<td>15</td>
<td>4</td>
</tr>
<tr>
<td>33</td>
<td>midgut NET</td>
<td>Yes</td>
<td>8</td>
<td>6</td>
</tr>
</tbody>
</table>

Table 1. Stool frequency pre and post enterade®. Data for 33 responders to enterade® as of June 2018.

RESULTS/CONCLUSIONS

- 33 out of 41 (80%) patients reported subjective improvement in diarrhea symptoms (Table 1)
- 51% (21/41) reported more than 50% reduction in diarrhea frequency.
- A prospective Phase II study (NCT03722511) of enterade in neuroendocrine tumor patients with quality of life limiting diarrhea is starting Q4 2018.

REFERENCES


Contact: amanchauhan@uky.edu

PROSPECTIVE PHASE 2 STUDY

Table 1. Stool frequency pre and post enterade®. Data for 33 responders to enterade® as of June 2018.